Lilian Wikström

IBT is a clinical stage pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. IBT is developing drug candidate IBP-9414 to prevent NEC in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT has an additional project in its portfolio, a second rare disease program, IBP-1016, for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available. Find more information about Infant Bacterial Therapeutics AB by visiting our website: www.ibtherapeutics.com Feel free to contact us at info@ibtherapeutics.com

SISP - Swedish Incubators & Science Parks, is a non-profit association with national coverage, its members hosting approx 5000 companies with around 70 000 employees. Focus is growth in knowledge-based companies. SISP‘s 65 members operate more than 70 creative environments, offer business development, work with clusters, industrial project development arenas, seed capital funds and more - effective collaboration with industry, public sector, universities and institutes.

Navigare Ventures is an early-stage investment company specialized in science-driven companies. Our core investment themes within deep tech are underpinned by our knowledge and network in a number of scientific fields, including AI, quantum technologies, data driven life science, synthetic biology and advanced materials. Navigare Ventures is based in Stockholm and is a wholly-owned subsidiary of Wallenberg Investments AB. With our investments, we support the industrial and societal impact of research by backing innovation for the long-term – while generating returns that strengthen the Wallenberg Foundations capacity to fund new academic research grants.

IBT is a clinical stage pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. IBT is developing drug candidate IBP-9414 to prevent NEC in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT has an additional project in its portfolio, a second rare disease program, IBP-1016, for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available. Find more information about Infant Bacterial Therapeutics AB by visiting our website: www.ibtherapeutics.com Feel free to contact us at info@ibtherapeutics.com

SISP - Swedish Incubators & Science Parks, is a non-profit association with national coverage, its members hosting approx 5000 companies with around 70 000 employees. Focus is growth in knowledge-based companies. SISP‘s 65 members operate more than 70 creative environments, offer business development, work with clusters, industrial project development arenas, seed capital funds and more - effective collaboration with industry, public sector, universities and institutes.

Swelife vill stärka life science i Sverige och förbättra folkhälsan. Swelife arbetar för att öka sammanhållningen och effektiviteten i hälso- och life science-sektorerna i Sverige, för att på så sätt skapa tillväxt och en bättre folkhälsa. Swelife är ett strategiskt innovationsprogram som är finansierat av Vinnova och projektens parter. Vi vill göra det möjligt för att kompetenser och resurser att användas på bästa sätt. Det gör vi genom nationell samverkan och samordning. Vi vill minska fragmenteringen inom life science i Sverige. Vi arbetar långsiktigt för att Sverige ska kunna erbjuda goda förutsättningar för en hälso- och life science-sektor som växer stadigt, ligger i framkant och är konkurrenskraftig på en global marknad. Vi vill accelerera de goda idéerna inom life science så att de kan växa till globala produkter och tjänster. Swelife arbetar för att vi som bor i Sverige ska tillgång till förebyggande insatser och kunskap för ett liv i hälsa. När vi är sjuka ska vi ha tillgång till innovativ, jämlik och individanpassad behandling. ---- Följ oss på Twitter: @swelife Följ oss på Facebook: https://www.facebook.com/swelifesweden/ Kontakt: Peter Nordström, programchef, peter.nordstrom@swelife.se, +46 705-19 12 20